Théa Open Innovation is a company belonging to the Théa Group, established by Jean-Frédéric Chibret in 2019. In today's world, where knowledge is increasingly vast and dispersed, a single company can no longer integrate all knowledge. It needs to attract external innovation and strengthen its collaborative capabilities. This is what Théa Open Innovation (TOI) is all about.
Théa Open Innovation
Open Innovation as a complement to knowledge
Théa Open Innovation: Its Mission
Théa Open Innovation aims to identify, evaluate, and enhance new solutions for treating eye diseases. In the field of ocular health, the company is committed to establishing the most innovative collaborations with universities, eye care professionals, researchers, biotechnology companies, and startups around the world, through licensing agreements and/or equity participation.
What is the objective of Théa Open Innovation?
Continuing research to offer innovative molecules and/or delivery methods for ophthalmic products, further strengthening Théa's position as a leader and a trusted partner for healthcare professionals.
In the partnerships established, Théa Open Innovation aims to provide both:
- Its expertise in ophthalmology development and the necessary funding to conduct clinical trials in humans.
- Its ability to oversee the advanced stages of product development and commercialization.
Thus, Théa Open Innovation’s mission is to bring new projects to the R&D pipelines of Laboratoires Théa, in both the ophthalmological fields familiar to the group and in technologies that are further removed from its core business.
By sharing Théa's knowledge and engaging in dialogue with new partners, collaborative projects of excellence and therapeutic innovations in eye health can emerge. This also allows Laboratoires Théa to strengthen their presence worldwide, beyond Europe, where they are already well-established.
Many partnerships
For Théa Open Innovation, novelty, diversification, partnerships, and efficiency are the keys to the future. In recent years, numerous partnerships have been signed.
Gene and cell therapies, artificial intelligence, the Internet of Things (IoT), and more are some of the innovations around which new solutions are being developed at Théa and with its partners.
All ocular pathologies are at the heart of the work of the Théa Open Innovation team: Dry and wet Age-Related Macular Degeneration, hereditary degenerative retinal diseases such as LCA10 and Usher2a, glaucoma, dry eye, myopia, and more.
Among the third-party projects that Théa is most proud of is the partnership with Tilak Healthcare, creator of the first remote monitoring device in ophthalmology. Théa's teams are responsible for promoting this e-health service. Another notable project is 'Sepul,' which aims to develop two treatments for blinding orphan diseases (Usher 2A and Leber Congenital Amaurosis type 10).